{"entity":{"type":"insider","cik":"0001493056","url":"/insider/0001493056","json_url":"/insider/0001493056.json","name":"Klassen Preston","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":11,"n_filings":8,"first":"2013-05-30","last":"2025-06-04","span_basis":"filed_date"},"name_variants":[{"name":"Klassen Preston","source":"filing","n_filings":8,"first_seen":"2013-05-30","last_seen":"2025-06-04"}],"transactions":[{"id":5075224,"accession":"0000950170-25-081715","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-081715","line_url":"/filing/0000950170-25-081715#line-1","is_derivative":false,"issuer_cik":"0001493056","issuer_name":"Regulus Therapeutics Inc.","issuer_ticker":"RGLS","issuer_name_source":null,"issuer_url":"/issuer/0001493056","owner_cik":"0001493056","owner_name":"Klassen Preston","owner_display_name":"Klassen Preston","owner_url":"/insider/0001493056","role":"Director, Officer (President & Head of R & D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & Head of R & D","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12000.0,"shares_display":"12,000","price_per_share":7.9877,"price_display":"7.99","price_state":"stated","total_value":95852.4,"total_display":"95,852.40","total_whole":"95,852","shares_owned_after":48055.0,"shares_owned_after_display":"48,055","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-03","filed_date":"2025-06-04","scope":"insider"},{"id":4455000,"accession":"0000950170-25-005880","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-005880","line_url":"/filing/0000950170-25-005880#line-1","is_derivative":false,"issuer_cik":"0001493056","issuer_name":"Regulus Therapeutics Inc.","issuer_ticker":"RGLS","issuer_name_source":null,"issuer_url":"/issuer/0001493056","owner_cik":"0001493056","owner_name":"Klassen Preston","owner_display_name":"Klassen Preston","owner_url":"/insider/0001493056","role":"Director, Officer (President & Head of R & D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & Head of R & D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31445.0,"shares_display":"31,445","price_per_share":1.2632,"price_display":"1.26","price_state":"stated","total_value":39721.324,"total_display":"39,721.32","total_whole":"39,721","shares_owned_after":36055.0,"shares_owned_after_display":"36,055","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-13","filed_date":"2025-01-15","scope":"insider"},{"id":8182540,"accession":"0001209191-23-005271","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-005271","line_url":"/filing/0001209191-23-005271#line-1","is_derivative":false,"issuer_cik":"0001493056","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001493056","owner_cik":"0001493056","owner_name":"Klassen Preston","owner_display_name":"Klassen Preston","owner_url":"/insider/0001493056","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":380605.0,"shares_display":"380,605","price_per_share":0.4132,"price_display":"0.41","price_state":"stated","total_value":157265.986,"total_display":"157,265.99","total_whole":"157,266","shares_owned_after":541905.0,"shares_owned_after_display":"541,905","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-26","filed_date":"2023-01-27","scope":"insider"},{"id":6572817,"accession":"0001209191-22-024951","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-024951","line_url":"/filing/0001209191-22-024951","is_derivative":false,"issuer_cik":"0001493056","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001493056","owner_cik":"0001493056","owner_name":"Klassen Preston","owner_display_name":"Klassen Preston","owner_url":"/insider/0001493056","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":44748.0,"shares_display":"44,748","price_per_share":0.5021917471171896,"price_display":"0.50","price_state":"stated","total_value":22472.0763,"total_display":"22,472.08","total_whole":"22,472","shares_owned_after":923683.0,"shares_owned_after_display":"923,683","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-19","filed_date":"2022-04-20","scope":"insider","n_lines":2},{"id":5491476,"accession":"0001209191-21-034596","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-034596","line_url":"/filing/0001209191-21-034596#line-1","is_derivative":false,"issuer_cik":"0001493056","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001493056","owner_cik":"0001493056","owner_name":"Klassen Preston","owner_display_name":"Klassen Preston","owner_url":"/insider/0001493056","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20547.0,"shares_display":"20,547","price_per_share":3.6352,"price_display":"3.64","price_state":"stated","total_value":74692.4544,"total_display":"74,692.45","total_whole":"74,692","shares_owned_after":20547.0,"shares_owned_after_display":"20,547","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-20","filed_date":"2021-05-20","scope":"insider"},{"id":8116727,"accession":"0001209191-19-002953","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-19-002953","line_url":"/filing/0001209191-19-002953#line-5","is_derivative":false,"issuer_cik":"0001080709","issuer_name":"ARENA PHARMACEUTICALS INC","issuer_ticker":"ARNA","issuer_name_source":null,"issuer_url":"/issuer/0001080709","owner_cik":"0001493056","owner_name":"Klassen Preston","owner_display_name":"Klassen Preston","owner_url":"/insider/0001493056","role":"Officer (EVP and CMO)","role_mark":"O","role_mark_label":"Officer (EVP and CMO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CMO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":44.0,"price_display":"44.00","price_state":"stated","total_value":132000.0,"total_display":"132,000.00","total_whole":"132,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-08","filed_date":"2019-01-08","scope":"insider"},{"id":8116719,"accession":"0001209191-19-002953","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-002953","line_url":"/filing/0001209191-19-002953","is_derivative":false,"issuer_cik":"0001080709","issuer_name":"ARENA PHARMACEUTICALS INC","issuer_ticker":"ARNA","issuer_name_source":null,"issuer_url":"/issuer/0001080709","owner_cik":"0001493056","owner_name":"Klassen Preston","owner_display_name":"Klassen Preston","owner_url":"/insider/0001493056","role":"Officer (EVP and CMO)","role_mark":"O","role_mark_label":"Officer (EVP and CMO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CMO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16000.0,"shares_display":"16,000","price_per_share":41.6916475,"price_display":"41.69","price_state":"stated","total_value":667066.36,"total_display":"667,066.36","total_whole":"667,066","shares_owned_after":400.0,"shares_owned_after_display":"400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-07","filed_date":"2019-01-08","scope":"insider","n_lines":2},{"id":5506913,"accession":"0001181431-13-041737","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-13-041737","line_url":"/filing/0001181431-13-041737#line-2","is_derivative":false,"issuer_cik":"0001382911","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001382911","owner_cik":"0001493056","owner_name":"Klassen Preston","owner_display_name":"Klassen Preston","owner_url":"/insider/0001493056","role":"Officer (SVP, Head Global Development)","role_mark":"O","role_mark_label":"Officer (SVP, Head Global Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Head Global Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":71229.0,"shares_display":"71,229","price_per_share":7.16,"price_display":"7.16","price_state":"stated","total_value":509999.64,"total_display":"509,999.64","total_whole":"510,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-25","filed_date":"2013-07-29","scope":"insider"},{"id":5257501,"accession":"0001181431-13-031632","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-13-031632","line_url":"/filing/0001181431-13-031632#line-2","is_derivative":false,"issuer_cik":"0001382911","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001382911","owner_cik":"0001493056","owner_name":"Klassen Preston","owner_display_name":"Klassen Preston","owner_url":"/insider/0001493056","role":"Officer (SVP, Head Global Development)","role_mark":"O","role_mark_label":"Officer (SVP, Head Global Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Head Global Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28771.0,"shares_display":"28,771","price_per_share":7.2072,"price_display":"7.21","price_state":"stated","total_value":207358.3512,"total_display":"207,358.35","total_whole":"207,358","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-28","filed_date":"2013-05-30","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":11,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":9,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":11},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001505512","name":"Regulus Therapeutics Inc.","url":"/issuer/0001505512","role":"Director, Officer (President & Head of R & D)","n_filings":2,"first_seen":"2025-01-15","last_seen":"2025-06-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001634379","name":"Metacrine, Inc.","url":"/issuer/0001634379","role":"Director, Officer (President & CEO)","n_filings":3,"first_seen":"2021-05-20","last_seen":"2023-01-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001080709","name":"ARENA PHARMACEUTICALS INC","url":"/issuer/0001080709","role":"Officer (EVP and CMO)","n_filings":1,"first_seen":"2019-01-08","last_seen":"2019-01-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001382911","name":"Orexigen Therapeutics, Inc.","url":"/issuer/0001382911","role":"Officer (SVP, Head Global Development)","n_filings":2,"first_seen":"2013-05-30","last_seen":"2013-07-29"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001493056","retrieved_at":"2026-08-25T09:31:05+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}